ORPHAZYME
DEAD

Serial Number

79180936

Owner

Orphazyme A/S

Attorney

John Paul Oleksiuk

Filing Date

Dec 1, 2015

Add to watchlist:

No watchlists yet
View on USPTO

ORPHAZYME Trademark

Serial Number: 79180936 • Registration: 5139414

ORPHAZYME is a trademark filed by Orphazyme A/S on December 1, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Orphazyme A/S (15 trademarks)

Copenhagen 2200N , DK

Entity Type: 99

Orphazyme ApS

c/o COBIS A/S
DK-2200 København N , DK

Entity Type: 16

Trademark Details

Filing Date

December 1, 2015

Registration Date

February 14, 2017

Published for Opposition

November 29, 2016

Cancellation Date

August 25, 2023

Goods & Services

Pharmaceutical and medical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; chemical-pharmaceutical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; all of the aforementioned with the exclusion of veterinary preparations and ingredients, supplements for food, and medicated foodstuffs for animals

Chemicals used in industry and in science; proteins for use in science and in manufacture; biochemicals, namely, polypeptides for scientific, research and commercial use; with the exclusion of chemicals used in the food industry and animal food industry and ingredients for foodstuffs for animals

Industrial analysis and research services; basic research and clinical research, hereunder for medicine and vaccine development; all the aforementioned services with the exclusion of services relating to the veterinary sector

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 25, 2025 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
May 27, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
May 6, 2024 INTS
INVALIDATION PROCESSED
May 6, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 25, 2024 INTR
CANCELLED SECTION 71
Aug 25, 2023 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jul 10, 2022 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 14, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jun 12, 2021 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 8, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 8, 2021 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 8, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 8, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 8, 2021 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 5, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 5, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 5, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 5, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 5, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 5, 2021 COAR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 25, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 25, 2019 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 7, 2018 TCCA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 30, 2018 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Aug 31, 2017 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 23, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 1, 2017 FICS
FINAL DISPOSITION PROCESSED
Jun 1, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 14, 2017 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 2, 2017 NREP
REGISTERED-PRINCIPAL REGISTER
Feb 14, 2017 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 22, 2016 NREP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 29, 2016 NPUB
PUBLISHED FOR OPPOSITION
Nov 29, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 9, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 22, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 18, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 5, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2016 CRFA
ASSIGNED TO LIE
Oct 2, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 26, 2016 TROA
REFUSAL PROCESSED BY IB
May 13, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 28, 2016 RFCS
REFUSAL PROCESSED BY MPU
Mar 28, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 26, 2016 RFCR
NON-FINAL ACTION WRITTEN
Mar 25, 2016 CNRT
NON-FINAL ACTION WRITTEN
Mar 25, 2016 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 2, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 28, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 21, 2016 REPR